PNEUMOCOCCAL VACCINE

FDA expands use of Prevnar 13 to include ages 6-17 years; now approved for ages 6 weeks - 17 years (before 18th birthday) and 50 years and older. (01-25-13) FDA approval letter | current package insert

Podcast: Prevent Pneumonia
Dr. Kathleen Dooling with the CDC explains what pneumonia is, its symptoms, and how to prevent it. [Released 5/23/2012; Run time 4:50]

FDA expands use of Prevnar 13 vaccine for people ages 50 and older
Link to Press Announcement (12-30-11)

CDC report summarizing data on the immunogenicity and safety of PCV13 in adults and outlining key additional evidence requested by ACIP to formulate recommendations for its use. MMWR 2012;61(21):394. (6-1-12)

Pneumococcal Conjugate (PCV13) Vaccine Information Statements:

PCV13 (4/16/10)
PCV7 (12/9/08) Use until supply of vaccine is exhausted
Other languages (including Spanish)
RTF file (for use in electronic systems)

Pneumococcal Polysaccharide (PPSV23) Vaccine Information Statements :

PPSV23 (10/06/09)
Other languages (including Spanish)
RTF file (for use in electronic systems)

This page was last updated on February 21, 2013